Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), Granada, Spain.
Instituto de Investigación Biosanitaria de Granada, (Ibs.GRANADA), Granada, Spain.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Nov-Dec;16(6):e2013. doi: 10.1002/wnan.2013.
Pancreatic cancer is one of the tumors with poor prognosis and low survival due to late diagnosis, high resistance, and very limited effective therapeutic options. Thus, new pharmacological treatments are necessary to improve the prognosis of patients. In this context, nanoparticles represent an efficient system for transporting and administering therapeutic molecules. Furthermore, siRNA can be used in cancer treatment to selectively inhibit the expression of any target gene. Therefore, nanoparticles associated with siRNA have been tested as a new therapeutic strategy to solve the pancreatic cancer treatment failure in the clinical setting. The current article presents a systematic revision of the literature of the last 10 years in which nanoparticles loading siRNA are used in pancreatic cancer. This research was carried out in three databases (PubMed, Scopus, and Web of Science) obtaining 164 articles from which 37 were selected. Our results show an overall view of the high effectiveness of this new therapy that combines nanoparticles with genetic therapy in pancreatic cancer suggesting that siRNA-based medicines will likely open up a new therapeutic era in the treatment of this type of tumors.
胰腺癌由于诊断较晚、耐药性高以及有效的治疗方法非常有限，导致预后较差，生存率低。因此，需要新的药理学治疗方法来改善患者的预后。在这种情况下，纳米颗粒代表了一种用于运输和给药治疗分子的有效系统。此外，siRNA 可用于癌症治疗，以选择性抑制任何靶基因的表达。因此，已将与 siRNA 结合的纳米颗粒作为一种新的治疗策略进行了测试，以解决临床环境中胰腺癌治疗失败的问题。本文对过去 10 年中使用负载 siRNA 的纳米颗粒治疗胰腺癌的文献进行了系统综述。这项研究在三个数据库（PubMed、Scopus 和 Web of Science）中进行，共获得了 164 篇文章，从中选择了 37 篇。我们的研究结果表明，将纳米颗粒与基因治疗相结合的这种新疗法具有很高的疗效，提示基于 siRNA 的药物可能会开创治疗这类肿瘤的新治疗时代。
